News GenoScreen Expertise

Adebiotech is organising a new day dedicated to innovative approaches in the fight against antibiotic resistance. The event will take place on September 16, 2021 at the Genopôle (Campus 1) in Evry-Courcouronnes - FRANCE.

Conferences will address preventive actions (microbiota, immunomodulation, new vaccines...), innovations in diagnostics (AI and Big data, metagenomics, new rapid diagnostics...), and some new therapeutic approaches (phagotherapy, antimicrobial peptides, bacteriocins...). The event will close with a round table/discussion on the marketing of new treatments, their financing and regulatory aspects.

During Session 2 - Innovative Diagnostics, which will take place from 11:30 am to 12:30 pm, Nelly BADALATO, Ph.D. R&D Project Manager at GenoScreen will talk about "Targeted Sequencing: a toolbox for antibiotic resistance monitoring and diagnosis".

For more information
(Only in French)

New training sessions in Bioinformatics and Targeted Metagenomics are available for 2020, don't hesitate to sign up!

Two exceptional strains of tuberculosis, isolated from East African patients with multi-resistant forms of the disease, have been discovered thanks to the use of our molecular test, Deeplex® Myc-TB.

GenoScreen will participate in in-cosmetics® global from June 30 to July 2, 2020, in Barcelona, Spain.

Researchers from the Lille Centre for Infection and Immunity (CNRS/INSERM/Institut Pasteur de Lille/University of Lille/CHU Lille), INRAE, GenoScreen and from Brazilian (Belo Horizonte), Scottish (Glasgow) and Danish (Copenhagen) laboratories have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favours secondary bacterial superinfection. Published in Cell Reports on March 3, 2020, these results open up new prospects for the prevention and treatment of bacterial pneumonia, a major cause of death in elderly or vulnerable people infected with the influenza virus.

A new study evaluated the impact of probiotic yeast S. boulardii CNCM I-745 on lipid profile in a hypercholesterolemia model in hamsters, combining analyses of intestinal microbial communities carried out via our Metabiote solutions.

The World Health Organisation (WHO) and other international organisations (including the World Organisation for Animal Health (OIE) and the International Union Against Tuberculosis and Lung Disease), have recently called for action to accurately diagnose and treat zoonotic1 tuberculosis in people, caused by Mycobacterium bovis2. Its contribution to human tuberculosis, otherwise primarily caused by Mycobacterium tuberculosis, may be globally underestimated. Nationally representative data on this zoonosis are especially lacking in the world regions (Asia, Africa) where the burden is presumably the highest.

M. bovis is a bacterium responsible for bovine tuberculosis, which is also capable of infecting humans. This bacterium frequently causes extrapulmonary tuberculosis in people, which is difficult to diagnose. Also, in contrast to M. tuberculosis, M. bovis is naturally resistant to pyrazinamide, an important antibiotic in the standard short course tuberculosis treatment.

Accurate diagnosis of M. bovis is therefore important to define appropriate patient treatment. This diagnosis can also guide the detection of infected animals and contaminated food sources (meat, dairy products, etc.), representing zoonotic risks that can escape TB control measures.  However, the most commonly used phenotypic and molecular diagnostic tests do not differentiate M. bovis from M. tuberculosis.

To address these problems, Al Ashkar and colleagues used the new Deeplex® Myc-TB test to reveal for the first time the national prevalence of zoonotic tuberculosis in a lower-middle-income country, namely Lebanon. Unlike the other tests, this comprehensive assay developed by GenoScreen enables the users to distinguish M. bovis from M. tuberculosis, identify more than 100 other mycobacterial species, and to simultaneously detect resistance to pyrazinamide, as well as to 14 other anti-tuberculosis drugs. The test can be applied directly on clinical samples, with a turnaround time of one to two days, instead of weeks when using culture-based tests.

The use of the Deeplex® Myc-TB test, which specifically identifies M. bovis, will thus help better detect zoonotic infections, allowing definition of more appropriate treatment of patients and providing guidance to uncover zoonotic sources.

 

1. Zoonosis: human disease contracted from an animal or animal product source (for instance: cattle, dairy products, meat…)

2. Olea-Popelka F, Muwonge A, Perera A, Dean AS, Mumford E, Erlacher-Vindel E, Forcella S, Silk BJ, Ditiu L, El Idrissi A, Raviglione M, Cosivi O, LoBue P, Fujiwara PI. Zoonotic tuberculosis in human beings caused by Mycobacterium bovis-a call for action. Lancet Infect Dis. 2017 Jan;17(1):e21-e25. doi:10.1016/S1473-3099(16)30139-6. Epub 2016 Sep 30. Review. PubMed PMID: 27697390

GenoScreen will participate in the 6th edition of NutrEvent on October 22 and 23 in Rennes, France.

By continuing your visit to this site, you accept the use of statistics cookies
More information I accept Decline